Westfield Capital Management Co. LP Acquires Shares of 703 Medpace Holdings, Inc. $MEDP

Westfield Capital Management Co. LP bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 703 shares of the company’s stock, valued at approximately $221,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Victory Capital Management Inc. lifted its position in shares of Medpace by 41.7% during the 1st quarter. Victory Capital Management Inc. now owns 23,979 shares of the company’s stock worth $7,306,000 after buying an additional 7,051 shares during the last quarter. Private Advisor Group LLC raised its stake in Medpace by 12.3% during the first quarter. Private Advisor Group LLC now owns 2,502 shares of the company’s stock worth $762,000 after acquiring an additional 275 shares in the last quarter. Kestra Private Wealth Services LLC boosted its stake in shares of Medpace by 5.6% in the 1st quarter. Kestra Private Wealth Services LLC now owns 2,199 shares of the company’s stock valued at $670,000 after purchasing an additional 116 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Medpace in the 1st quarter valued at approximately $8,388,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Medpace during the 1st quarter valued at approximately $60,000. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on MEDP shares. Mizuho increased their price objective on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. TD Cowen increased their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research note on Friday, October 24th. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and raised their price objective for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and upped their target price for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Finally, Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $487.18.

Insider Activity

In other news, Director Robert O. Kraft sold 6,472 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $591.85, for a total transaction of $3,830,453.20. Following the completion of the sale, the director owned 833 shares of the company’s stock, valued at $493,011.05. This trade represents a 88.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO August J. Troendle sold 36,196 shares of Medpace stock in a transaction on Friday, August 29th. The shares were sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares of the company’s stock, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 201,308 shares of company stock worth $114,534,479. Company insiders own 20.30% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $591.82 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The company has a 50 day simple moving average of $549.46 and a two-hundred day simple moving average of $432.72. The company has a market capitalization of $16.67 billion, a PE ratio of 41.39, a P/E/G ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.